Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial

Analysis (n=515) found an increase of 10% time at optimal antihypertensive dose reduced 180-day heart failure related admission or all-cause death (HR 0.89, 95%CI 0.81-0.98) & all-cause mortality (0.84, 0.73-0.95), and improved quality of life, without increasing adverse effects.

SPS commentary:

A related commentary discusses this research, highlighting that the underuse of high value treatments and therapeutic inertia in heart failure was the reason for the original STRONG-HF investigation.  This new analysis provides further evidence that swift dose optimisation is important in heart failure treatment, and effort is required to overcome the inertia in optimal management of this disease.

JAMA Cardiology

Resource links:

Editorial